Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044837 | 0.77 | ALDH1A1 (0.41) | CYP19A1 | |
| SCHEMBL4564456 | 0.74 | CYP19A1 (0.69) | CYP19A1IDO1TDO2CYP3A4TSHR | |
| SCHEMBL4557447 | 0.74 | CYP19A1 (0.46) | CYP19A1CYP3A4CYP2C19 | |
| SCHEMBL2749688 | 0.73 | CYP19A1 (0.45) | CYP19A1MGLLCYP3A4 | |
| SCHEMBL4592205 | 0.72 | CYP19A1 (0.44) | CYP19A1IDO1 | |
| SCHEMBL4600552 | 0.71 | CYP19A1 (0.42) | CYP19A1IDO1KMT2ACYP1A1CYP3A4 | |
| SCHEMBL5049548 | 0.70 | CCR1 (0.42) | KMT2ACYP3A4CYP2C19 | |
| SCHEMBL2717291 | 0.70 | ESR1 (0.50) | IDO1KMT2AMGLLCYP3A4CYP2C19 | |
| SCHEMBL4600205 | 0.69 | CYP19A1 (0.41) | CYP19A1CYP1A1 | |
| SCHEMBL24465605 | 0.68 | CYP19A1 (0.36) | CYP19A1CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405231-B2 | Anticancer agents; inhibitors of the HER-signaling pathway with decreased toxicity, better solubility and improved pharmacokinetic profile; e.g. 1-[4-(4-(2-[(E)-2-(4-Methanesulfinyl-phenyl)-vinyl]-oxazol-4-ylmethoxy)-phenyl)-butyl]-1H-[1,2,3]triazole | HOFFMANN-LA ROCHE INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1401972-B1 | PIGMENT PASTE | AKZO NOBEL COATINGS INT BV (NL) | 2008-06-11 | — | — | EP | disclosed |
| US-7235574-B2 | Pentafluorosulfanyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| CN-1930153-A | Pentafluorosulfanyl compounds, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-03-14 | — | — | CN | disclosed |
| CN-1930156-A | Oxidized thioether derivatives of styryl-azoles and their use as HER tyrosine kinases inhibitors | HOFFMANN LA ROCHE (CH) | 2007-03-14 | — | — | CN | disclosed |
| EP-1725549-A1 | PENTAFLUOROSULFANYL COMPOUNDS, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| EP-1725551-A1 | OXIDIZED THIOETHER DERIVATIVES OF STYRYL-AZOLES AND THEIR USE AS HER TYROSINE KINASES INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005095388-A1 | PENTAFLUOROSULFANYL COMPOUNDS, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095393-A1 | OXIDIZED THIOETHER DERIVATIVES OF STYRYL-AZOLES AND THEIR USE AS HER TYROSINE KINASES INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| US-20050203064-A1 | Novel oxidized thioether derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | US | disclosed |
| US-20050197370-A1 | Novel pentafluorosulfanyl compounds | HOFFMANN-LA ROCHE INC. | 2005-09-08 | — | — | US | disclosed |
| US-6787598-B2 | INCLUDING A BRANCHED ALKYD; ALKYD RESINS ALLOW HIGH PIGMENT CONTENTS, WHILE THE SOLVENT CONTENT CAN BE KEPT VERY LOW TO MIX PAINTS COMPLYING WITH VOLATILE ORGANIC COMPOUND (VOC) REGULATIONS | AKZO NOBEL N.V. (NL) | 2004-09-07 | — | — | US | disclosed |
| EP-1401972-A1 | PIGMENT PASTE | Akzo Nobel Coatings International B.V. (NL) | 2004-03-31 | — | — | EP | disclosed |
| US-20020193471-A1 | Including a branched alkyd; alkyd resins allow high pigment contents, while the solvent content can be kept very low to mix paints complying with volatile organic compound (VOC) regulations | AKZO NOBEL N.V. (NL) | 2002-12-19 | — | — | US | disclosed |
| WO-2002096997-A1 | PIGMENT PASTE | AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197370-A1 | Novel pentafluorosulfanyl compounds | SF3B5, SF3B1, SF3B3 | CYP19A1 635/4885IDO1 3765/4885TDO2 3818/4885 |
| US-20050203064-A1 | Novel oxidized thioether derivatives | SULT1E1, CYP4F3, GPX4 | CYP19A1 229/4885IDO1 3562/4885TDO2 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.